Role Of Ramosetron 5-HT3 Receptor Antagonists In The Treatment Of Irritable Bowel Syndrome (Diarrhea Dominant)

Abstract

Background: One of the most common functional gastrointestinal illnesses, irritable bowel syndrome (IBS), significantly impairs quality of life. The present study was conducted to assess the role of the 5-HT3 receptor antagonist Ramosetron in the treatment of irritable bowel syndrome. Materials and Methods: 60 patients with IBS of both genders were divided into three
groups of 20 each. Group I (control), Group II (placebo), and Group III (test). Patients were given 5 mg Ramosetron daily for 3 months, and parameters such as duration of IBS, severity of abdominal pain or discomfort (0–4), stool form (appearance, 1–7), stool frequency (bowel movements per day), adverse events, etc. were recorded